An experimental one-time gene therapy from biotech company uniQure continues to show signs of slowing Huntington’s disease four years after treatment, offering potentially important evidence that gene therapy could alter the course of a devastating inherited neurological disorder for which no approved disease-modifying treatment currently exists. The treatment, called ifezuntirgene...
Menu